Bethlehem, Pa — Neuromonics Inc has announced that Richard Giancola has joined the company as chief executive officer and member of its board of directors. Giancola, who was most recently vice president and general manager, Latin America, for Cochlear Americas, brings more than 25 years of experience driving multi-million dollar sales growth for global medical device companies. In his new role, Giancola will lead the global organization to gain further market acceptance and continue the growth of Neuromonics.
 
“Rick has a proven track record of growing emerging markets for medical device treatments into multi-million dollar businesses,” said Ron West, chairman of Neuromonics. “We are confident he has the experience, knowledge and drive to continue Neuromonics growth and help reach our ultimate goal— providing tinnitus sufferers worldwide with the safest and most effective treatment available.”
 
Prior to joining Neuromonics, Giancola was a senior executive with global cochlear implant market leader, Cochlear Americas, since 1999.  While at Cochlear Americas, Giancola increased sales to become a multi-million dollar business and managed year-over-year revenue growth exceeding 30 percent. Giancola brings an extensive background in the medical device industry to Neuromonics including positions with American Hospital Supply, Deseret Medical and 10 years as founder and president of Landmark Medical Exports Inc, an export management and consulting firm specializing in Latin America.
 
“I am pleased to be joining the company at this time of rapid growth and I look forward to furthering the company’s leadership in tinnitus research and treatment,” said Giancola. “Recent data proving the efficacy and durability of the Neuromonics Tinnitus Treatment and increasingly widespread clinician adoption demonstrates the value of our innovative and effective device.”